Sickle Cell Disease - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 199 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H2 2016, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 8, 9, 1, 24, 7 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 1 molecules, respectively for Sickle Cell Disease.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 5
Sickle Cell Disease Overview 6
Therapeutics Development 7
Sickle Cell Disease - Therapeutics under Development by Companies 9
Sickle Cell Disease - Therapeutics under Investigation by Universities/Institutes 13
Sickle Cell Disease - Pipeline Products Glance 14
Sickle Cell Disease - Products under Development by Companies 18
Sickle Cell Disease - Products under Investigation by Universities/Institutes 21
Sickle Cell Disease - Companies Involved in Therapeutics Development 22
Sickle Cell Disease - Therapeutics Assessment 56
Drug Profiles 68
Sickle Cell Disease - Dormant Projects 176
Sickle Cell Disease - Discontinued Products 179
Sickle Cell Disease - Product Development Milestones 180
Appendix 191

List of Tables

Number of Products under Development for Sickle Cell Disease, H2 2016 14
Number of Products under Development for Sickle Cell Disease - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Comparative Analysis by Unknown Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2016 28
Sickle Cell Disease - Pipeline by Acceleron Pharma, Inc., H2 2016 29
Sickle Cell Disease - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 30
Sickle Cell Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 31
Sickle Cell Disease - Pipeline by Advinus Therapeutics Ltd, H2 2016 32
Sickle Cell Disease - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 33
Sickle Cell Disease - Pipeline by Angiocrine Bioscience, Inc., H2 2016 34
Sickle Cell Disease - Pipeline by Bio Products Laboratory Ltd, H2 2016 35
Sickle Cell Disease - Pipeline by bluebird bio, Inc., H2 2016 36
Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Company, H2 2016 37
Sickle Cell Disease - Pipeline by Complexa, Inc., H2 2016 38
Sickle Cell Disease - Pipeline by CRISPR Therapeutics, H2 2016 39
Sickle Cell Disease - Pipeline by CSL Limited, H2 2016 40
Sickle Cell Disease - Pipeline by Editas Medicine, Inc., H2 2016 41
Sickle Cell Disease - Pipeline by Emmaus Medical, Inc., H2 2016 42
Sickle Cell Disease - Pipeline by Errant Gene Therapeutics, LLC, H2 2016 43
Sickle Cell Disease - Pipeline by Gamida Cell Ltd., H2 2016 44
Sickle Cell Disease - Pipeline by Gilead Sciences, Inc., H2 2016 45
Sickle Cell Disease - Pipeline by Global Blood Therapeutics, Inc., H2 2016 46
Sickle Cell Disease - Pipeline by Johnson & Johnson, H2 2016 47
Sickle Cell Disease - Pipeline by La Jolla Pharmaceutical Company, H2 2016 48
Sickle Cell Disease - Pipeline by Merck & Co., Inc., H2 2016 49
Sickle Cell Disease - Pipeline by Modus Therapeutics Holding AB, H2 2016 50
Sickle Cell Disease - Pipeline by Morphogenesis, Inc., H2 2016 51
Sickle Cell Disease - Pipeline by NKT Therapeutics, Inc., H2 2016 52
Sickle Cell Disease - Pipeline by Novartis AG, H2 2016 53
Sickle Cell Disease - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 54
Sickle Cell Disease - Pipeline by Pfizer Inc., H2 2016 55
Sickle Cell Disease - Pipeline by PharmaEssentia Corporation, H2 2016 56
Sickle Cell Disease - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 57
Sickle Cell Disease - Pipeline by Protagonist Therapeutics Inc., H2 2016 58
Sickle Cell Disease - Pipeline by ReveraGen BioPharma, Inc., H2 2016 59
Cell Disease - Pipeline by Sancilio & Company, Inc., H2 2016 60
Sickle Cell Disease - Pipeline by Sangamo BioSciences, Inc., H2 2016 61
Sickle Cell Disease - Pipeline by Selexys Pharmaceuticals Corporation, H2 2016 62
Assessment by Monotherapy Products, H2 2016 63
Assessment by Combination Products, H2 2016 64
Number of Products by Stage and Target, H2 2016 66
Number of Products by Stage and Mechanism of Action, H2 2016 69
Number of Products by Stage and Route of Administration, H2 2016 72
Number of Products by Stage and Molecule Type, H2 2016 74
Sickle Cell Disease - Dormant Projects, H2 2016 183
Sickle Cell Disease - Dormant Projects (Contd..1), H2 2016 184
Sickle Cell Disease - Dormant Projects (Contd..2), H2 2016 185
Sickle Cell Disease - Discontinued Products, H2 2016 186